Phase I dose escalation study of the anti-CD2 monoclonal antibody, siplizumab, with DA-EPOCH-R in aggressive peripheral T-cell lymphomas.

ABSTRACT:

SUBMITTER: Roswarski J 

PROVIDER: S-EPMC6372084 | biostudies-literature | 2018 Jun

REPOSITORIES: biostudies-literature